Please try another search
Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.
The drugs account for 40% of the company's Q3 revenue when its COVID vaccine and antiviral treatment, Paxlovid are excluded. The five drugs are -Eliquis to prevent blood clots, Vyndaqel for cardiomyopathy, Xeljanz for rheumatoid arthritis, Ibrance for breast cancer and Xtandi for prostate cancer.
It is also worth noting that the future of the coronavirus is unclear. If it subsides, it will hit demand for Paxlovid and COVID vaccines which accounted for 52% of revenue for the quarter.
CEO Albert Bourla plans to deal with these future losses by generating revenue from its recent acquisitions, leveraging its in-house drugs and vaccine pipeline as well as focusing on respiratory syncytial virus, migraines, and ulcerative colitis.
However, based on the current chart it seems investors are not convinced about the strategy.
Note the rising volume accompanying the downside breakout and the dead drop in that participation when the price rebounds.
I would have preferred a sharper spike as the pattern completed, but bears may feel that the sparse volume of the return move compensates, showing an obvious negative divergence.
Still, the price found resistance by the bottom of the triangle which confirms the overselling within the pattern, and the 200-day moving average is a rational bullish stronghold.
Measure the pattern's height and deduct that figure from the breakout point. The assumption is that the same interest that dominated the price structure will maintain its struggle below it, therefore repeating the $16.31 move from $46.82 to $30.51.
Conservative traders should wait for confirmation that resistance persists, such as with a long red candle, before risking a short.
Moderate traders would be content with a weekly close below the pattern.
Aggressive traders could short at will, according to their strategy, incorporating their timing, budget, and temperament. Here is a generic example:
Trade Sample - Aggressive Short Position
Disclaimer: At the time of publication, the author had no positions in the securities mentioned.
Fixed-income stocks have outperformed the broader market by a wide margin in the past 12 months. I remain positive on companies with growing dividend payouts, strong fundamentals,...
Costco’s January sales results are confirmation that the pandemic was just the beginning. The warehouse club allows consumers to buy the brand names they want and avoid...
Thursday was another great session for the S&P 500, with the index adding 1.4% and extending this week’s bounce off of 4k support. But this was expected, as I wrote Wednesday...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.